Statin-Induced Diplopia: A Rare Side Effect

Anu Suria Ganason; Chitra  Suluraju; Fuziah  Paimin; Yafizah Yahaya; Fathima Begum  Syed Mohideen

doi:10.33102/mjosht.v7i3.181

Authors

Anu Suria Ganason Primary Health Care Department, Faculty of Medicine and Health Sciences, Universiti Sains Islam Malaysia, Bandar Baru Nilai, 71800, Nilai, Negeri Sembilan.
Chitra Suluraju Klinik Kesihatan Putrajaya Presint 9, 62250 Putrajaya, Wilayah Persekutuan Putrajaya.
Fuziah Paimin Klinik Kesihatan Putrajaya Presint 9, 62250 Putrajaya, Wilayah Persekutuan Putrajaya.
Dr Yafizah Yahaya Primary Health Care Department, Faculty of Medicine and Health Sciences, Universiti Sains Islam Malaysia, Bandar Baru Nilai, 71800, Nilai, Negeri Sembilan.
Fathima Begum Syed Mohideen Primary Health Care Department, Faculty of Medicine and Health Sciences, Universiti Sains Islam Malaysia, Bandar Baru Nilai, 71800, Nilai, Negeri Sembilan.

DOI:

https://doi.org/10.33102/mjosht.v7i3.181

Keywords:

statin; diplopia; dyslipidemia; HMG-CoA reductase; neurology

Abstract

Statin is one of the most effective medication to date in treating dyslipidemia. Moreover, statin is the most available in health clinics due to its cost-effectiveness. However, statin must be used with caution due to its severe rare side effects. Ocular disorder secondary to statin is rarely reported. In this case, statin-induced lateral gaze diplopia, worst on the left lateral gaze, was noted in a middle-aged Malay man. He had underlying dyslipidemia and was started on simvastatin 20mg at night three days before developing diplopia. He was otherwise well and had no other medical illnesses. There were no other neurological signs and abnormal ocular signs. Investigations were done and revealed no other abnormalities. The patient's symptom resolved gradually over eight weeks after discontinuation of the statin. Thus, this case highlights the important key point of anticipating this severe rare side effect of statin, which may be irreversible.

Downloads

Download data is not yet available.

References

MOH. Clinical Practice Guidelines: Management of Dyslipidaemia 2017 (5th Edition). Ministry of Health Malaysia. 2017;17(July):1–107.

Stroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., ... & Wiklund, O. (2015). Statin-associated muscle symptoms: impact on statin therapy. European Atherosclerosis Society consensus panel statement on assessment, aetiology and management. European heart journal, 36(17), 1012-1022.

Thapar, M., Russo, M. W., & Bonkovsky, H. L. (2013). Statins and liver injury. Gastroenterology & hepatology, 9(9), 605.

Mizranita, V., & Pratisto, E. H. (2015). Statin-associated ocular disorders: the FDA and ADRAC data. International journal of clinical pharmacy, 37(5), 844-850.

Fraunfelder, F. W., & Richards, A. B. (2008). Diplopia, blepharoptosis, and ophthalmoplegia and 3 hydroxy 3 methyl glutaryl CoA reductase inhibitor use. Ophthalmology, 115(12), 2282-2285.

Mason, R. P., Walter, M. F., & Jacob, R. F. (2004). Effects of HMG CoA reductase inhibitors on endothelial function: role of microdomains and oxidative stress. Circulation, 109(21 supply 1), 2-34.

Alves, M., Miranda, A., Narciso, M. R., Mieiro, L., & Fonseca, T. (2015). Diplopia: a diagnostic challenge with common and rare etiologies. The American journal of case reports, 16, 220.

Subramanian P., Lee M. S., Eggenberger E., Volpe N. J., Liu G. T., Bruce B. B. (2014). NIH Public Access, 120, 1–13.

Zhou, L. Y., Liu, T. J., & Li, X. M. (2016). Adult reference values of the computerized diplopia test. International journal of ophthalmology, 9(11), 1646.

Lareb bijwerkingen centrum. Statins and diplopia. 2016.